Latest News and Press Releases

Icelandirect contract manufacturer of supplements, vitamins, and nutraceuticals for human and pet brands, completes its FSSC 22000 Version 6 certification.

Phase 2 and Phase 3 trials are reshaping expectations across obesity, oncology, gene editing, autoimmune disease, and neurological disorders.

Pre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatment to First-In-Human clinical trial ZURICH, Switzerland, May 27, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (“NewcelX”;...

Translational data demonstrate induction of both innate and adaptive antiviral and anti-tumor specific immune responses capable of controlling tumor growth

ODDIFACT obtient la désignation médicament orphelin de l'EMA pour l'infliximab dans la maladie de Kawasaki, après la FDA. Essai KIDCARE dans The Lancet.

ODDIFACT obtient la désignation médicament orphelin de l'EMA pour l'infliximab dans la maladie de Kawasaki, après la FDA. Essai KIDCARE dans The Lancet.

Silver Spring, MD, May 20, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration announced today that it issued warning letters to eight retailers for selling unauthorized tobacco products,...

NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Psyence BioMed Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company focused on the development and supply of nature-derived...

AI Products Showcase

Washington, DC, May 14, 2026 (GLOBE NEWSWIRE) -- The Personalized Medicine Coalition released a new report documenting the U.S. Food and Drug Administration’s continued progress in advancing...